Indicatum

Investera med insikt - Data visar vägen!

Bevaka (0)

Vicore Pharma Holding

Lista

Small Cap

Sektor

Health Care

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. Vicore Pharma Holding AB (publ) has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.


Ranks


Kursgraf

Länk till dynamisk (zoombar) graf för större skärmar


Nuvarande och kommande formation


MA Rank

Free stock photo of 4k wallpaper, bridge, daylight
Photo by Markus Spiske on Pexels

Välkommen till Indicatum!

Vi bygger vår nya plattform och kan tyvärr inte ta emot nyregistreringar just nu, men registrera din e-postadress nedan så får du en notis när vi lanserar tjänsten.

Vi ser fram emot att höra från dig!

Vi spammar inte!
Din email kommer endast att användas för att meddela dig när plattformen lanseras

Rulla till toppen